Injectafer denied as non-formulary by Humana?

Humana's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Injectafer as Non-Formulary

A non-formulary denial means Injectafer (ferric carboxymaltose) is not included on Humana's current drug formulary tier for your plan, or is placed on a tier requiring additional approval. This is a coverage-structure decision, not a clinical one — but it is fully appealable through a formulary exception process, particularly when there is a documented clinical reason why formulary alternatives are inadequate.

Formulary exceptions are a recognized pathway under federal law and are granted when the available formulary options have been tried and failed, are medically contraindicated for the specific patient, or are otherwise clinically inappropriate. Humana is required to have a formulary exception process.

## Federal Appeal Framework

ACA §2719 requires external review rights for non-grandfathered plans after internal remedies are exhausted. ERISA §503 protects employer-plan members with a full-and-fair review right. For formulary exception requests that are denied, the four-month external-review window applies from the date of final denial. Expedited external review is available when the clinical situation is urgent.

Note: some plan types (grandfathered or self-insured plans not electing external review) may have different rules — check your Summary Plan Description.

## Concrete Appeal Steps

1. Request a formulary exception in writing, citing clinical need — this is distinct from a standard grievance and may move faster. 2. Obtain Humana's list of formulary-preferred IV iron agents and have your prescriber document why each is clinically unsuitable for this patient. 3. Submit the internal appeal with clinical documentation within the plan's stated deadline. 4. If the formulary exception is denied, escalate to the full internal appeal process, then to external review. 5. Confirm with Humana's member services whether a peer-to-peer call is available — it is often an efficient path to resolution for formulary exceptions.

## Documentation to Gather

• Diagnosis confirmation: Current chart notes establishing the underlying condition requiring IV iron.
• Formulary-alternative history: Documentation of any formulary IV iron agent tried, including dates, outcomes, and clinical rationale for why it is inadequate — or prescriber attestation that it is clinically inappropriate without having been tried.
• Clinical severity: Objective documentation justifying IV rather than oral iron replacement.
• Prescriber medical-necessity and exception letter: Specifically requests the formulary exception, explains why formulary alternatives do not meet this patient's clinical needs, and references the FDA-approved Injectafer label.

## Criteria-Mapping Structure

Obtain Humana's formulary exception criteria (available from the plan or Humana's provider portal) and the FDA-approved Injectafer prescribing label. Build a response table:

| Formulary exception criterion | Supporting documentation | |---|---| | Non-formulary drug provides unique clinical benefit | [Prescriber letter rationale] | | Formulary alternatives tried and failed or contraindicated | [Dates, agents, outcomes or clinical reason] | | Diagnosis and severity support IV route | [Chart notes, labs] |

Addressing each exception criterion directly, with dated chart evidence, gives the appeal the best chance of resolution before external review.